$DRTS News

Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT® for Pancreatic Cancer Patients in Korea

Alpha Tau Medical Inks MoU With Samsung Medical Center In Seoul Regarding Potential Clinical Study In Pancreatic Cancer Patients

How Investors Are Reacting To Alpha Tau Medical (DRTS) Expanded Brain Cancer Trial

HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $16 Price Target

Alpha Tau Announces FDA Approval to Expand Alpha DaRT® U.S. Recurrent Glioblastoma REGAIN Trial; New Trial Data to be Presented at SNO 2026 Annual Meeting

Alpha Tau Medical Receives FDA Approval For Investigational Device Exemption Supplement To Expand Its U.S. REGAIN Study

Alpha Tau to Participate in October Investor Conferences

Alpha Tau: Approaching Massive Year-End; Pounding The Table On Potential GBM Breakthrough

Barclays Maintains Overweight on Alpha Tau Medical, Raises Price Target to $30

Alpha Tau to Participate in September Investor Conferences

Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following Strong Demand and Multiple Expansions

HC Wainwright & Co. Maintains Buy on Alpha Tau Medical, Raises Price Target to $16

Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Alpha Tau Medical Q2 EPS $(0.50) Misses $(0.14) Estimate

Alpha Tau Medical (DRTS) Is Down 5.7% After Early-Stop Success In Alpha DaRT Combo Trial

HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $15 Price Target

Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for Success

Alpha Tau Medical Announces Positive Data In Head And Neck Cancer Treatment Study, Hitting 100% Objective Response Rate Across Nine Evaluable Patients

HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $15 Price Target

Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center